SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant attention as community members analyze its resilience amidst geopolitical tensions and supply chain complexities while weighing the impact of its major Small Modular Reactor (SMR) contracts and defense partnerships. Investors are actively discussing the company's long-term transformation, focusing on whether current volatility provides an optimal entry point or signals broader headwinds for its commercial aerospace engine business.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors focus on its role in building decentralized AI infrastructure, with significant community excitement surrounding its potential as a long-term asset akin to early-stage growth plays. Discussions are heavily focused on the project's subnet ecosystem, institutional interest, and the strategy of staking as a means to accumulate value despite broader market volatility.

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's Nasdaq debut has triggered intense debate, with the stock drawing record trading volumes and massive institutional inflows despite significant concerns over its lack of profitability and sky-high valuation. While bullish investors view the company as a transformative leader in space and AI infrastructure, the community remains divided as traders focus on the upcoming options chain launch and the technical implications of its massive market capitalization.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent extension securing exclusivity through 2041 and subsequent analyst price target upgrades, fueling a surge in volume and stock price to multi-year highs. The community is actively debating the implications of this news for a potential buyout while closely monitoring the status of European regulatory milestones and management's ongoing clinical development strategy.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is facing volatility as traders react to a double beat on Q1 earnings, while simultaneously processing the company's announcement of a new $1.5 billion shelf offering. Despite strong revenue growth and a record $900 million backlog, sentiment is fractured by the dilutive potential of the offering and institutional liquidity rotating toward the upcoming SpaceX IPO.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant volatility as investors weigh disappointing monthly sales data against anticipated long-term milestones like J-code reimbursement and potential European market expansion. The community remains deeply divided, with many shareholders dismissing the price drop as algorithmic manipulation and short-term weakness while expressing frustration over management's lack of transparency regarding recent executive departures.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to the community's relentless focus on organic growth and the proliferation of diverse, community-led initiatives like consumer products and IRL brand integration. Supporters are actively discussing their conviction in these projects, emphasizing a 'work-not-gamble' culture while steadily accumulating tokens to build long-term value.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is capturing attention as traders monitor a potential breakout from long-term consolidation, with the community actively debating whether recent ecosystem expansions and IoT narratives can drive a shift in momentum. While bullish supporters are focused on potential institutional adoption and increased trading volume, skeptics remain vocal, highlighting ongoing concerns about tokenomics, historical price performance, and the emergence of competing projects within the broader ecosystem.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and downward pressure despite reporting strong quarterly revenue, leaving investors divided between those focused on the potential of the Elevidys gene therapy pipeline and those frustrated by a perceived lack of management action on the share price. The community is actively discussing potential leadership transitions, rumors of a strategic reorganization or buyout, and the impact of broader biotech sector headwinds on the symbol's recent performance.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is experiencing intense volatility and community division following news of an indictment involving Super Micro Computer executives, with traders heavily debating the risks of holding a 2x leveraged ETF amidst the stock's significant decline. The community is focused on the impact of potential delistings and reverse splits while weighing the aggressive short interest against the potential for a rebound in the underlying equity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.57% and -64.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +253.07% and +56.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommen...

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Time to Sell?

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Here's What Happened...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat...

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

What is HC Wainwright's Forecast for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Thursday, March 12th. HC...

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

FHTXFoghorn Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FHTX News